Phase 2 N=2 LC Drug Eluting Bead for Treatment of Liver Cancer Which Cannot be Surgically Removed
Hepatocellular Carcinoma
Primary: The Number of Patients in the Cohort Effectively Downstaged to Transplant Eligibility With the LC BeadTM
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=50 Chemoembolization in Treating Patients With Primary Liver Cancer or Metastases to the Liver
Liver Cancer · Metastatic Cancer
Primary: Time to Progression — 2.3; 7.2 Months
N/A N=23 Stereotactic Body Radiotherapy for Liver Tumors
Liver Metastases · Hepatocellular Carcinoma · Intrahepatic Cholangiocarcinoma
Primary: Local Tumor Recurrence Rate — 4; 0 Participants
Phase 2 N=19 Selumetinib in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Adult Primary Hepatocellular Carcinoma · Advanced Adult Primary Liver Cancer · Localized Unresectable Adult Primary Liver Cancer
Primary: Number of Participants With Radiographic Objective Response (OR) — 0 participants
N/A N=20 LC Bead Embolization Agent With Doxorubicin in the Treatment Liver Metastasis From Melanoma
Stage IV Melanoma
Primary: Incidence of Adverse Events — 465 Events
Phase 2 N=64 PET/CT in Diagnosing Patients With Liver Cancer Undergoing Surgical Resection
Adult Hepatocellular Carcinoma · Localized Resectable Adult Liver Carcinoma
Primary: Fluorine-18 (18F) Fluoromethylcholine (FCH) PET/CT Parameters for Assessing Hepatocellular Carcinoma (HCC): Area Under the Receiver Operating Characteristic Curve…
Phase 2 N=16 Treatment of Liver Metastases With Electrochemotherapy
Liver Metastases
Primary: Evaluation of Toxicity Related to Electrochemotherapy (Toxicity, Symptoms) — 0; 0; 0 events
Phase 2 N=23 Treatment of Liver Metastases With Electrochemotherapy (ECTJ) Phase II
Liver Metastases
Primary: Evaluation of Safety Related to Electrochemotherapy — 20; 3; 0; 0 Participants
Phase 2 N=46 Bevacizumab in Treating Patients With Unresectable Nonmetastatic Liver Cancer
Adult Primary Hepatocellular Carcinoma · Localized Unresectable Adult Primary Liver Cancer · Recurrent Adult Primary Liver Cancer
Primary: Progression-free Survival — 65 percentage of participants
Phase 2 N=38 Intra-hepatic Chemotherapy in Patients With Liver Metastases From Breast Cancer and Limited Extrahepatic Disease
Metastatic Breast Cancer · Liver Metastases
Primary: Response Rate — 2; 13; 21; 1 Participants
Phase 2 N=37 Sorafenib Tosylate and Pembrolizumab in Treating Patients With Advanced or Metastatic Liver Cancer
Advanced Adult Hepatocellular Carcinoma · Child-Pugh Class A · Stage III Hepatocellular Carcinoma
Primary: Overall Response Rate Defined as Partial or Complete Response Per Immune-related Response Evaluation Criteria in Solid Tumors — 8; 19 Participants
N/A N=84 Evaluation of Liver Cancer With Magnetic Resonance Imaging (MRI)
Hepatocellular Carcinoma · HCC
Primary: SubStudy 1: Apparent Diffusion Coefficient (ADC) — 1.43 1x10^-3 mm^2/s
Phase 2 N=39 Lipiodol as an Imaging Biomarker in Patients With Primary and Metastatic Liver Cancer
Liver Cancer
Primary: Tumor Response by Response Evaluation Criteria in Solid Tumors (RECIST) — 1; 1; 17; 15 Participants
Phase 2 N=47 Study of Bavituximab and Sorafenib In Patients With Advanced Liver Cancer
Hepatocellular Carcinoma · Liver Cancer
Primary: Median Radiographic Time to Progression (TTP) Calculated From Treatment Initiation to First Evidence of Disease Progression or Last Follow-up. — 6.7 months
Phase 2 N=33 Tivozanib in Treating Patients With Liver Cancer That Is Metastatic or Cannot Be Removed by Surgery
Advanced Adult Hepatocellular Carcinoma · Non-Resectable Hepatocellular Carcinoma
Primary: PFS, Assessed Using Standard RECIST Criteria — 58 percentage of participants
Phase 2 N=42 Yttrium-90 Radioembolization Using Glass Microspheres (TheraSphere) for Patients With Liver Metastases
Colorectal Neoplasms · Neuroendocrine Tumors · Cholangiocarcinoma
Primary: Number of Participants With Adverse Events — 42 participants
Phase 2 N=151 TheraSphere for the Treatment of Liver Metastases
Colorectal Cancer · Carcinoma, Neuroendocrine · Neoplasm Metastasis
Primary: Hepatic Progression-free Survival According to Response Evaluation Criterian in Solid Tumors (RECIST) — 3.0; 17.9; 2.9; 3.4 Months
Phase 2 N=49 Liver Resection and Floxuridine Plus Fluorouracil and Leucovorin in Treating Patients With Liver Metastases From Colorectal Cancer
Colorectal Cancer · Metastatic Cancer
Primary: 2 Year Disease-free Survival . — 9 percentage of participants
Phase 3 N=356 Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Advanced Adult Hepatocellular Carcinoma · Recurrent Hepatocellular Carcinoma · Stage III Hepatocellular Carcinoma AJCC v7
Primary: Overall Survival — 8.9; 10.5 month — p=0.24
N/A N=3 Stereotactic Body Radiation Therapy (SBRT) for Liver Mets
Liver Metastases
Primary: Maximum Tolerated Dose (MTD) — 60 Gy
Phase 1 N=27 Nivolumab and Yttrium Y 90 Glass Microspheres in Treating Patients With Advanced Liver Cancer
Stage IIIA Hepatocellular Carcinoma · Stage IIIB Hepatocellular Carcinoma · Stage IIIC Hepatocellular Carcinoma
Primary: Maximum Tolerated Dose (MTD) — 240 mg of nivolumab, IV
Phase 2 N=16 Sorafenib and Nivolumab in Treating Participants With Unresectable, Locally Advanced or Metastatic Liver Cancer
Stage III Hepatocellular Carcinoma AJCC v8 · Stage IIIA Hepatocellular Carcinoma AJCC v8 · Stage IIIB Hepatocellular Carcinoma AJCC v7
Primary: Maximum Tolerated Dose (MTD) (Part 1 Only) — 400 milligrams (mg) once per day
Phase 2 N=137 A Phase II Open Label Study of BMS-582664 in Locally Advanced or Metastatic Hepatocellular Cancer
Hepatocellular Carcinoma (HCC)
Primary: Progression Free Survival (PFS) Rate at 6 Months Per Independent Response Review Committee (IRRC) in Cohort A — 22.4 Percent of participants
Phase 2 N=11 Cisplatin or Carboplatin and Sorafenib in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery
Liver Cancer
Primary: Number of Subjects Experiencing Adverse Events — 2 participants
Phase 2 N=30 Chemoembolization and Bevacizumab in Treating Patients With Liver Cancer That Cannot Be Removed With Surgery
Liver Cancer
Primary: Neovessel Formation as Measured by Angiogram at 14 Weeks — 2; 3 participants
Phase 2 N=48 SIR-Spheres® 90Y Microspheres Treatment of Uveal Melanoma Metastasized to Liver
Stage IV Uveal Melanoma
Primary: Clinical Benefit Rate of Previously Treated and Naive Patients — 0; 0; 7; 6 Participants
Phase 2 N=23 A Clinical Research Study to Determine Whether PD 0332991 May Be Effective in Treating Patients With Liver Cancer
Advanced Hepatocellular Carcinoma · HCC · Liver Cancer
Primary: Time to Disease Progression — 8 months
Phase 3 N=235 Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
Hepatocellular Carcinoma · Unresectable Hepatocellular Carcinoma
Primary: Progression-free Survival (PFS) — 9.3; 8.4 months — p=0.4
Phase 2 N=50 Intra-arterial Y-90 TheraSpheres for Hepatic Metastases From Solid Tumors
Liver Neoplasms
Primary: Time to Progression (TTP) of the Treated Lesion(s) According to RECIST Criteria
Phase 2 N=24 Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Liver Cancer
Primary: Maximum Tolerated Dose (Phase I) — 2; 3; 0; 0 Participants